Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nan Chi

Showing results (181-190 of 188) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 188 results.
Nature Communications|November 30, 2023
Author Correction: A two-dimensional mid-infrared optoelectronic retina enabling simultaneous perception and encodingFakun Wang, Fangchen Hu, Mingjin Dai, et al.
Journal of Medicinal Chemistry|October 12, 2011
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoformTimothy P Heffron, Binqing Wei, Alan Olivero, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorTimothy P Heffron, Megan Berry, Georgette Castanedo, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Pageof 19

Showing results (181-190 of 188) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 188 results.
Nature Communications|November 30, 2023
Author Correction: A two-dimensional mid-infrared optoelectronic retina enabling simultaneous perception and encodingFakun Wang, Fangchen Hu, Mingjin Dai, et al.
Journal of Medicinal Chemistry|October 12, 2011
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoformTimothy P Heffron, Binqing Wei, Alan Olivero, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorTimothy P Heffron, Megan Berry, Georgette Castanedo, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.
Journal of Medicinal Chemistry|August 30, 2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer Adrian J Folkes, Khatereh Ahmadi, Wendy K Alderton, et al.
Pageof 19